Business Daily from THE HINDU group of publications
Thursday, Dec 28, 2006
ePaper
Business Daily from THE HINDU group of publications Thursday, Dec 28, 2006 ePaper |
|
|
|
|
|
|
|
Corporate
-
Regulatory Bodies & Rulings
Our Bureau
Hyderabad , Dec. 27 Dr Reddy's Laboratories Ltd today got the final approval for Ondansetron Hydrochloride, the generic equivalent of the blockbuster drug `Zofran', from the US Food and Drug Administration (USFDA), as well as a 6-month marketing exclusivity. The Hyderabad based pharma major announced that the USFDA has granted final approval for its Abbreviated New Drug Application (ANDA) for Ondansetron Hydrochloride Tablets in dosages of 4mg, 8mg, 16mg and 24mg.
Marketing exclusivity
As the first company to file an ANDA containing a paragraph IV certification for this product, the company has also been awarded a 180-day period of marketing exclusivity, a press release from the company said. The company's Ondansetron Hydrochloride tablets are the AB-rated generic equivalent of GlaxoSmithKline's `Zofran' tablets, a product indicated for the prevention of nausea and vomiting associated with cancer treatment. The brand product has annual IMS sales of approximately $639 million. Today's approval follows an order by the US Court of Appeals for the DC Circuit denying Apotexs request that the FDA not approve the company's generic Zofran products pending a determination of its motion for a preliminary injunction. Dr Reddy's will commence the shipment of this product shortly. Mr G.V. Prasad, Vice-Chairman and CEO of the company, said, "We are pleased with the final approval of our generic version of Zofran with 180-days of marketing exclusivity. With six product introductions to date in the current year, we are making good progress in building a sustainable base in generics business with potential upsides in the US in the medium term. This reaffirms our commitment to developing one of the largest pipelines in the US generic industry."
More Stories on : Regulatory Bodies & Rulings | Pharmaceuticals | Dr. Reddy's Laboratories Ltd
Article E-Mail :: Comment :: Syndication :: Printer Friendly Page
|
Stories in this Section |
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | The Hindu ePaper | Business Line | Business Line ePaper | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |
Copyright © 2006, The
Hindu Business Line. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of
The Hindu Business Line
|